Vertex scores world-first approval

Posted 20 November 2023 AM

Vertex has won the first-ever regulatory approval of a therapy based on the CRISPR gene-editing technology, with the UK's MHRA giving it the tick for two indications, sickle cell disease and transfusion-dependent beta-thalassaemia.

The treatment, previously known as exa-cel (exagamglogene autotemcel) and now branded Casgevy, may well make its way to Australia "over time" an Australian spokesperson for Vertex told Pharma in Focus. 

To see the whole article, please login